Phase I Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of Debio 0932, a Novel Hsp90-inhibitor, Administered Orally, in Patients With Advanced Solid Tumours or Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2015
At a glance
- Drugs CUDC 305 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Debiopharm
- 31 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Feb 2013 Phase Ib results will be presented by Debiopharm at a medical meeting in 2013 according to a Curis media release.
- 27 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History